Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica
Novartis announced FDA approval for Cosentyx (secukinumab) to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The 150-mg dose showed 40.5% remission at Week 52 vs. 20.5% for placebo. This is Cosentyx's 11th U.S. indication. The approval follows positive Phase III trial results, with the drug demonstrating steroid-sparing effects. Novartis also noted ongoing regulatory reviews in other regions.
How this was made
The 30-second read
Why it matters
The new indication could increase Cosentyx sales and improve Novartis' pipeline credibility.
Market read
Regulatory approval is a primary catalyst for biotech stocks, likely boosting NVS.
What to watch
Potential safety concerns from adverse events could temper enthusiasm.
Background
Novartis announced the first FDA approval of Cosentyx for PMR, its 11th US indication.
Ticker impact
Novartis received FDA approval for Cosentyx in polymyalgia rheumatica, adding a new indication.
upward pressure as investors price in the new indication
FDA approvals are material events; the added indication opens a sizable patient population and may boost sales.
Market effects
Strengthens the biotech/autoimmune therapeutic sector with a new IL-17 indication.
Positive for US pharma stocks; may influence European peers with similar pipelines.
Adds to global biotech innovation narrative, modestly supportive for worldwide pharma indices.
Counterpoint
If the market has already priced in the approval, the stock may see limited upside.
Key entities
- CompanyNovartis
Swiss pharmaceutical company receiving FDA approval.
- DrugCosentyx
IL-17 biologic now approved for PMR.




